CD72 gene expression in immune thrombocytopenia

References

• Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585–596
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008
   PubMed Web of Science ®Google Scholar
• Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, Han ZC. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005; 90: 914–923
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87: 4245–4254
   PubMed Web of Science ®Google Scholar
• Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008; 112: 1325–1328
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123–1124
   PubMed Web of Science ®Google Scholar
• Kalwak K, Gorczynska E, Wojcik D, Toporski J, Turkiewicz D, Slociak M, Latos-Grazynska E, Boguslawska-Jaworska J, Chybicka A. Late-onset idiopathic thrombocytopenic purpura correlates with rapid B-cell recovery after allogeneic T-cell-depleted peripheral blood progenitor cell transplantation in children. Transplant Proc 2002; 34: 3374–3377
   PubMed Web of Science ®Google Scholar
• Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924–2930
   PubMed Web of Science ®Google Scholar
• Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, Jia H, Yang R, Han ZC. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78: 139–143
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168–186
   PubMed Web of Science ®Google Scholar
• Wu HJ, Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol 2009; 29: 12–21
   PubMed Web of Science ®Google Scholar
• Kumanogoh A, Shikina T, Watanabe C, Takegahara N, Suzuki K, Yamamoto M, Takamatsu H, Prasad DV, Mizui M, Toyofuku T, et al. Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment. Int Immunol 2005; 17: 1277–1282
   PubMed Web of Science ®Google Scholar
• Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: A novel mechanism for regulating B cell signaling. Immunity 2000; 13: 621–631
   PubMed Web of Science ®Google Scholar
• Delaire S, Elhabazi A, Bensussan A, Boumsell L. CD100 is a leukocyte semaphorin. Cell Mol Life Sci 1998; 54: 1265–1276
   PubMed Web of Science ®Google Scholar
• Bougeret C, Mansur IG, Dastot H, Schmid M, Mahouy G, Bensussan A, Boumsell L. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol 1992; 148: 318–323
   PubMed Web of Science ®Google Scholar
• Pan C, Baumgarth N, Parnes JR. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 1999; 11: 495–506
   PubMed Web of Science ®Google Scholar
• Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, Yukawa K, Ikawa M, Okabe M, Parnes JR, et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: Defective B and T cell activation in CD100-deficient mice. Immunity 2000; 13: 633–642
   PubMed Web of Science ®Google Scholar
• Kaneko U, Toyabe S, Hara M, Uchiyama M. Increased mutations of CD72 transcript in B-lymphocytes from adolescent patients with systemic lupus erythematosus. Pediatr Allergy Immunol 2006; 17: 565–571
   PubMed Web of Science ®Google Scholar
• Nakano S, Morimoto S, Suzuki J, Mitsuo A, Nakiri Y, Katagiri A, Nozawa K, Amano H, Tokano Y, Hashimoto H, et al. Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis. Autoimmunity 2007; 40: 9–15
   PubMed Web of Science ®Google Scholar
• Smith AJ, Gordon TP, Macardle PJ. Increased expression of the B-cell-regulatory molecule CD72 in primary Sjogren's syndrome. Tissue Antigens 2004; 63: 255–259
   PubMedGoogle Scholar
• Xu J, Lu S, Tao J, Zhou Z, Chen Z, Huang Y, Yang R. CD72 polymorphism associated with child-onset of idiopathic thrombocytopenic purpura in Chinese patients. J Clin Immunol 2008; 28: 214–219
   PubMed Web of Science ®Google Scholar
• Venkataraman C, Muthusamy N, Muthukkumar S, Bondada S. Activation of lyn, blk, and btk but not syk in CD72-stimulated B lymphocytes. J Immunol 1998; 160: 3322–3329
   PubMed Web of Science ®Google Scholar
• Venkataraman C, Lu PJ, Buhl AM, Chen CS, Cambier JC, Bondada S. CD72-mediated B cell activation involves recruitment of CD19 and activation of phosphatidylinositol 3-kinase. Eur J Immunol 1998; 28: 3003–3016
   PubMed Web of Science ®Google Scholar
• Subbarao B, Mosier DE. Induction of B lymphocyte proliferation by monoclonal anti-Lyb 2 antibody. J Immunol 1983; 130: 2033–2037
   PubMed Web of Science ®Google Scholar
• Subbarao B, Mosier DE. Activation of B lymphocytes by monovalent anti-Lyb-2 antibodies. J Exp Med 1984; 159: 1796–1801
   PubMed Web of Science ®Google Scholar
• Kumanogoh A, Kikutani H. The CD100-CD72 interaction: A novel mechanism of immune regulation. Trends Immunol 2001; 22: 670–676
   PubMed Web of Science ®Google Scholar
• Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci USA 1996; 93: 11780–11785
   PubMed Web of Science ®Google Scholar
• Ishida I, Kumanogoh A, Suzuki K, Akahani S, Noda K, Kikutani H. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: Implications for the regulation of immune and inflammatory responses. Int Immunol 2003; 15: 1027–1034
   PubMed Web of Science ®Google Scholar
• Kumanogoh A, Suzuki K, Ch'ng E, Watanabe C, Marukawa S, Takegahara N, Ishida I, Sato T, Habu S, Yoshida K, et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol 2002; 169: 1175–1181
   PubMed Web of Science ®Google Scholar
• Webber NP, Mascarenhas JO, Crow MK, Bussel J, Schattner EJ. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol 2001; 62: 1346–1355
   PubMed Web of Science ®Google Scholar
• Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000; 79: 507–513
   PubMed Web of Science ®Google Scholar
• Yoshimura C, Nomura S, Nagahama M, Ozaki Y, Kagawa H, Fukuhara S. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 2000; 64: 219–224
   PubMed Web of Science ®Google Scholar
• Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, Maniatis A, Mouzaki A. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103: 2645–2647
   PubMed Web of Science ®Google Scholar
• Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168: 3675–3682
   PubMed Web of Science ®Google Scholar
• Xiao C, Rajewsky K. MicroRNA control in the immune system: Basic principles. Cell 2009; 136: 26–36
   PubMed Web of Science ®Google Scholar
• Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM, Yin YB. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007; 16: 939–946
   PubMed Web of Science ®Google Scholar
• Wu KH, Peng CT, Li TC, Wan L, Tsai CH, Lan SJ, Chang MC, Tsai FJ. Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura. Br J Haematol 2005; 128: 849–852
   PubMed Web of Science ®Google Scholar
• Zhao H, Du W, Wang D, Gu D, Xue F, Ge J, Sui T, Yang R. The expression of IFN-gamma, IL-4, Foxp3 and perforin genes are not correlated with DNA methylation status in patients with immune thrombocytopenic purpura. Platelets 2010; 21: 137–143
   PubMed Web of Science ®Google Scholar
• Ogawara H, Handa H, Morita K, Hayakawa M, Kojima J, Amagai H, Tsumita Y, Kaneko Y, Tsukamoto N, Nojima Y, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 71: 283–288
   PubMed Web of Science ®Google Scholar